LISCure Biosciences is developing 'bacteria-based cancer immunotherapy' and 'microbiome therapy' for major therapeutic areas such as oncology, liver diseases, autoimmune diseases, and neuroscience. LISCure’s approach to therapeutics is developing different single bacterial strains for each pipeline.
LISCure’s proprietary candidate for ‘bacteria-based cancer immunotherapy (injection)’ is in the pre-IND stage and is being developed with a new modality of non-pathogenic bacteria. For ‘microbiome therapy (oral)’, LISCure has two (2) microbiome programs for liver diseases and autoimmune diseases in the clinical stage, and one (1) candidate for neuroscience in the IND-enabling stage.
LISCure Microbiology-based Technology (“LMT”) Platform ensures the sustainability in the discovery of new drug candidates and success in clinical trials. LMT Platform is comprised of the integrated and seamless processes of three pillars: therapeutic screening, microbial optimization, and microbiome database.